Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

Slides:



Advertisements
Similar presentations
© ANZDATA Registry CANCER CHAPTER CHAPTER 10. © ANZDATA Registry CharacteristicMyelomaNon-Myeloma n%n% Total (%)807153,37199 Country of residence Australia ,25683.
Advertisements

NEW PATIENTS COMMENCING TREATMENTS IN 2010 CHAPTER 2.
ANZDATA Registry Annual Report 2013 NEW PATIENTS CHAPTER 2.
Systemic diseases and the kidney Dr I.Sagiv M.D Nephrology & Hypertension services Hadassah-Hebrew university medical center Jerusalem.
Blair Grace Kylie Hurst Stephen McDonald CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN Annual Report—35th Edition ANZDATA Registry Annual Report.
Chapter 1 Incidence of End Stage Kidney Disease 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.
KDIGO guidelines glomerulonephritis Dr.. Overview Rationale for requirement of guidelines KDIGO: GN Guidelines  Scope Clinical Nephrology Conferences.
2016 Annual Data Report, Vol 2, ESRD, Ch 8
Characteristics of patients Without renal recovery
“Systemic Lupus Erythematosus” Renal features
Overzicht van relevante classificatiesystemen in de nefropathologie
Table 1.2.1: Total number of renal biopsies by centres, 2005 – 2012
Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.
Odd ratio of developing kidney failure figure 1
Volume 81, Issue 2, Pages (January 2012)
Mortality rates in incident ESRD patients figure 9
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
Dr. Mohammad Alkhowaiter, MD Consultant Nephrologist
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use  Mei-Ling Blank, Lianne.
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in Among a Racially and Ethnically Diverse US Population  John J. Sim,
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Volume 94, Issue 5, Pages (November 2018)
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Nat. Rev. Nephrol. doi: /nrneph
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Volume 57, Issue 1, Pages (January 2000)
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Chronic kidney disease (CKD), with a prevalence of 10% to 15%
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
Dr. Mohammad Alkhowaiter, MD Consultant Nephrologist
Chronic kidney disease (CKD), with a prevalence of 10% to 15%
Volume 92, Issue 2, Pages (August 2017)
Volume 67, Issue 5, Pages (May 2005)
Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.
Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.
Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.
The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.
No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.
Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.
Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.
Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.
Performance characteristics for multivariate assay SLE panel.
Study schemas. Study schemas. Upper panel: single-ascending dose study. Subjects with mild, stable systemic lupus erythematosus (SLE) were randomised to.
Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.
Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.
Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.
Serum proteins dysregulated at baseline in patients enrolled in the MUSE study subsetted by IFNGS test status, Cutaneous Lupus Erythematosus Disease Area.
Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.
Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)
SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.
Least squares (LS) mean (SE) changes from baseline in (A) Cutaneous Lupus Erythematosus Disease Area and Severity Index activity scores and (B) Tender.
Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.
Presence of autoreactive anti-HLA antibodies among SLE and RA subjects
Impact of skin damage on health-related quality of life.
Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.
Mean change from baseline over time in BILAG score,
Overall gene expression in monocyte subsets in patients and controls.
(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.
IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.
Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.
Trends in the incidence of renal failure in Australia
Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.
Incident cases of ESRD secondary to heroin-associated nephropathy, membranoproliferative glomerulonephritis type 1, HIV infection, and focal segmental.
Relative renal biopsy diagnosis frequencies of the most common glomerular disease subtypes according to patient age category and typical mode of clinical.
Presentation transcript:

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall (A) and by age, sex and race (B). Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall (A) and by age, sex and race (B). SLE, systemic lupus erythematosus; HTN, hypertension; DMII, diabetes mellitus type II; FSGS, focal segmental glomerulosclerosis; other GN, glomerulonephritis not attributed to SLE. Other includes tubular necrosis, IgA nephropathy, scleroderma, diabetes mellitus type I, multiple myeloma, other renal disorder and uncertain aetiology. Laura C Plantinga et al. Lupus Sci Med 2016;3:e000132 ©2016 by Lupus Foundation of America

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.